US equities |
INTC $63.70 ▼-30.82% AMZN $237.94 ▼-2.40% NVDA $201.75 ▼-5.57% MU $865.38 ▼-7.37% SNDK $1,123.89 ▼-15.50% GOOGL $277.85 ▼-2.10% AMD $497.01 ▼-12.25% SPCX $135.83 ▼-5.60%
FinancialContent

Articles published by Cognition Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
News headline image
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
< Previous 1 2 3 4 Next >